A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Advanced Cancer
DRUG: AB801|DRUG: Docetaxel
Number of Participants With Adverse Events, Up to 2 years|Dose Escalation Cohorts: Number of Participants With Dose-Limiting Toxicities (DLTs), Up to 2 years
Area Under the Plasma Drug Concentration-Time Curve (AUC), Predose, Up to 8 hours postdose|Maximum Concentration (Cmax) in Plasma, Predose, Up to 8 hours postdose|Time to Maximum Concentration (Tmax) in Plasma, Predose, Up to 8 hours postdose|Objective response rate (ORR) as Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Up to 2 years|Dose Expansion Cohorts: Duration of Response (DOR) as Assessed per RECIST v1.1, Up to 2 years
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.